Long-Term Follow-Up Study of AAV2hAQP1 for Radiation Induced Xerostomia

N/AActive Not RecruitingNCT05060341

MeiraGTx, LLC22 enrolled

Overview

This study is a long-term follow-up study for patients who have been administered AAV2hAQP1 in the Phase 1 Open-Label, Dose Escalation Study to Determine the Optimal Dose, Safety, and Activity in Subjects with Radiation Induced Parotid Gland Hypofunction and Xerostomia

This clinical trial is designed to assess the long-term safety and activity of intra-parotid administration of AAV2hAQP1 in subjects with radiation-induced parotid salivary hypofunction and xerostomia. After completion of their Month 12 Follow-Up visit in Study MGT016, subjects will be invited to enroll in this 4-year follow-up study during which they will be assessed for up to 60 months following study drug administration. This follow-up trial is a non-interventional study designed to collect data on longer-term safety and activity at 18, 24, 36, 48, and 60 months following study drug administration. Over the course of the study, subjects will undergo physical and oral examinations; vital sign measurements; weight measurements; AE assessments; concurrent medication assessments; sample blood collection for hematology and chemistry; urinalysis; ear, nose, and throat (ENT) screening for malignancy; imaging assessments (if indicated); salivary flow assessments; and questionnaire assessments.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Radiation-induced Xerostomia

Eligibility

Sex: ALLMin age: 18 YearsMax age: 81 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Are willing and able to provide informed consent 2. Received AAV2hAQP1 administered via Stensen's duct to a single or both parotid glands in the prior open-label, Phase 1, dose-escalation study (Study MGT016) 3. Are willing and able to adhere to the protocol and long-term follow-up Exclusion Criteria: 1\. Subjects unwilling or unable to meet with the requirements of the study will be excluded

Locations (4)

Leland Stanford Junior University

Stanford, California, United States

Brigham and Women's Hospital

Boston, Massachusetts, United States

Atrium Health

Charlotte, North Carolina, United States

Health Sciences North - Northeast Cancer Center

Greater Sudbury, Ontario, Canada

Outcomes

Primary Outcomes

• Incidence of AEs, treatment-emergent adverse events (TEAEs), and SAEs

Safety

Time frame: 4 years

Secondary Outcomes

Changes in saliva flow compared to baseline.

Changes in unstimulated and stimulated salivary output (mL/minute) of the treated parotid gland and/or whole saliva output as compared to baseline.

Time frame: 4 years

Changes in the McMaster Global Rate of Change relative to Baseline

This first part of this questionnaire asks the patient to evaluate their Dry Mouth relative to before treatment as better, worse, or the same. If better or worse, the patient is asked to rate the magnitude of change, on a scale of 1-7, with a higher score being a better outcome. This first part of this questionnaire asks the patient to evaluate how limited they are in daily activities due to dry mouth, relative to before treatment as better, worse, or the same. If better or worse, the patient is asked to rate the magnitude of change, on a scale of 1-7, with a higher score being a better outcome.

Time frame: 4 years

Changes in the Xerostomia Questionnaire relative to Baseline

The XQ is a series of 8 questions designed to assess the degree of xerostomia symptoms. Each question is a scale of 1-10, with high values indicating worse xerostomia.

Time frame: 4 years

Changes in the MD Anderson Symptom Inventory - Head and Neck

The MDASI-HN is a questionnaire consisting of 28 questions designed to assess the degree of xerostomia symptoms. Each question is a scale of 1-10, with high values indicating worse xerostomia.

Time frame: 4 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.